Development and Validation of Stability Indicating RP-HPLC Method for Estimation of Satranidazole from Its Formulation. (22nd December 2013)

• Record Type: Journal Article
• Authors: Pawar, Harshal Ashok; Joshi, Pooja Rasiklal
• Other Names: Sanches Silva A. Academic Editor.; Vazquez A. Academic Editor.
• Is Part Of: ISRN chromatography. Volume 2014(2014)
• Publication Date: 2013-12-22
• Subjects: Chromatographic analysis -- Periodicals; Chromatographic analysis; Electronic journals; Periodicals; Electronic journals; 543.8
• DOI: 10.1155/2014/689218
• Languages: English
• ISSNs: 2090-8636

Abstract

Abstract : Satranidazole is a new nitroimidazole derivative with potent antiamoebic action and is available in market in the form of tablet and dry syrup either alone or in combination with Ofloxacin. The present study involves the development of simple, accurate, precise, and reproducible reversed phase high performance liquid chromatography (RP-HPLC) method for determination of Satranidazole from its granular dosage form. Isocratic elution at a flow rate of 1.0 mL/min was employed on BDS Hypersil C18 (250 mm × 4.6 mm, 5 μ m) column at 25°C temperature. The mobile phase consists of 0.16% v/v orthophosphoric acid solution, pH 3: acetonitrile in the ratio of 60 : 40 v/v. The UV detection wavelength was 320 nm, and 20 μ L sample was injected. The retention time for Satranidazole was about 4.3 minutes. The method was validated for various parameters such as system suitability, precision, recovery, robustness, and ruggedness as per ICH guidelines. The validated RP-HPLC method was found to be specific, linear, precise, and accurate and can be successfully employed for the assay of Satranidazole taste masked granules coated with Eudragit E100 and marketed tablets.